Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo khoa hoc:" Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: A pilot randomized placebo-controlled trial"
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: A pilot randomized placebo-controlled trial | Hurt et al. Journal of Negative Results in BioMedicine 2011 10 1 http www.jnrbm.eom content 10 1 1 r M 1 JOURNAL OF NEGATIVE RESULTS IN BIOMEDICINE RESEARCH Open Access Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers A pilot randomized placebo-controlled trial Richard D Hurt1 2 Jon O Ebbert1 2 Ivana T Croghan1 Darrell R Schroeder3 Amit Sood4 J Taylor Hays4 Abstract Background Methylphenidate blocks the re-uptake of dopamine by binding to the dopamine transporter in the presynaptic cell membrane and increases extracellular dopamine levels. Similarities in neuropsychologic effects between nicotine and methylphenidate make it an intriguing potential therapeutic option. Previous research of methylphenidate in smokers has suggested a possible beneficial effect for the relief of nicotine withdrawal symptoms but showed no efficacy in helping smokers with attention deficit hyperactivity disorder ADHD to stop smoking. Methods To investigate potential efficacy for relieving nicotine withdrawal symptoms and promoting smoking abstinence we conducted a randomized double-blind placebo-controlled phase II study of once-a-day osmotic-release oral system methylphenidate OROS-MPH Concerta at a target dose of 54-mg day for 8 weeks compared with placebo in 80 adult cigarette smokers. Results Of the 80 randomized subjects and median smoking rate was 20 cigarettes per day. At the end of the medication phase the biochemically confirmed 7-day point prevalence smoking abstinence was 10 4 40 for the placebo group and 2.5 1 40 for the OROS-MPH group. Nicotine withdrawal was not found to differ significantly between treatment groups during the first 14 days following the start of medication prior to the target quit date p 0.464 or during the first 14 days following the target quit date p 0.786 . Conclusion We observed no evidence of efficacy of OROS-MPH to aid smokers to stop smoking. Although there are biologically plausible hypotheses